Literature DB >> 10584663

Levodopa in the treatment of Parkinson's disease: a consensus meeting.

Y Agid1, E Ahlskog, A Albanese, D Calne, T Chase, J De Yebenes, S Factor, S Fahn, O Gershanik, C Goetz, W Koller, M Kurth, A Lang, A Lees, P Lewitt, D Marsden, E Melamed, P P Michel, Y Mizuno, J Obeso, W Oertel, W Olanow, W Poewe, P Pollak, E Tolosa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10584663     DOI： 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  22 in total

1.  Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis.

Authors:  A Hartmann; J D Troadec; S Hunot; K Kikly; B A Faucheux; A Mouatt-Prigent; M Ruberg; Y Agid; E C Hirsch
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

Review 2.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

4.  Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.

Authors:  H Baas; F Zehrden; R Selzer; R Kohnen; J Loetsch; S Harder
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 6.  Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.

Authors:  B R Thanvi; T C N Lo
Journal:  Postgrad Med J       Date:  2004-08       Impact factor: 2.401

Review 7.  Parkinson's disease: is the initial treatment established?

Authors:  J Eric Ahlskog
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

8.  NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats.

Authors:  John E Kelsey; Stephen D Mague; Reyna S Pijanowski; Ryan C Harris; Nancy W Kleckner; Russell T Matthews
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 9.  Cabergoline : a review of its use in the treatment of Parkinson's disease.

Authors:  Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.

Authors:  D J Brooks; H Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.